FDA rule on investigational drugs permits expanded access under REMS
This article was originally published in Scrip
Executive Summary
The US FDA's final regulations on expanded access to investigational drugs allow medicines with risk evaluation and mitigation strategies (REMS) to be used by patients who would not normally qualify for treatment.